Compound News and Research

RSS

Almac, MGB Biopharma partner to manufacture MGB-BP3 gram positive antibacterial compound

MGB Biopharma and Almac's Sciences Business Unit have entered into a collaboration where Almac will manufacture the production of their lead gram positive antibacterial compound MGB-BP3.

17 Jan 2012

Animal study confirms dramatic effects of natural formula against prostate cancer

New animal study confirms the dramatic effects of a natural formula against aggressive prostate cancer tumors. Researchers at the Methodist Research Institute at Indiana University conducted the study on mice, using a human prostate cancer xenograft model.

17 Jan 2012

Links between deodorants and breast cancer refuted but more information needed: Study

A chemical present in cosmetics, food products and pharmaceuticals has been found in tissue samples from 40 women with breast cancer. A number of studies since 1998 have raised concerns about the potential role of these chemicals called parabens in breast cancer as they possess estrogenic properties. Estrogen is known to play a central role in the development, growth and progression of breast cancer.

16 Jan 2012

Scientists identify chemical signals that promote aggregation in roundworms

Scientists have long seen evidence of social behavior among many species of animals, both on the earth and in the sea. Dolphins frolic together, lions live in packs, and hornets construct nests that can house a large number of the insects. And, right under our feet, it appears that nematodes-also known as roundworms-are having their own little gatherings in the soil. Until recently, it was unknown how the worms communicate to one another when it's time to come together.

13 Jan 2012

AICAR might protect against heat stress in MH-susceptible individuals

Malignant hyperthermia (MH) is a life-threatening genetic muscle disorder, most commonly triggered in those at risk by certain types of drugs used during anesthesia. Heat stroke, on the other hand, most commonly occurs in individuals in response to physical exertion in hot/humid environments. While their common triggers may differ, the signs associated with MH and heat stroke are remarkably similar - uncontrolled muscle contractions, dangerous increases in body temperature, and muscle breakdown leading to the release of toxins in the blood which may cause cardiac arrhythmias and death. Immediate treatment for these conditions is crucial.

13 Jan 2012

ISU receives U.S. patent for phytol-derived adjuvant

While conducting research on cancer, Swapan Ghosh and a team of graduate and doctoral students discovered a phytol-derived adjuvant. That adjuvant formula just became U.S. Patent No. 8,088,395.

13 Jan 2012

GC-Rise presents at J.P. Morgan's 30th annual Healthcare Conference

GC-Rise Pharmaceutical Co. Ltd, in which European healthcare venture capital firm INVENTAGES holds a majority stake, has debuted at J.P. Morgan's 30th annual Healthcare Conference in the United States.

13 Jan 2012

Chlorophyll in green vegetables offers protection against cancer

A recent study at Oregon State University found that the chlorophyll in green vegetables offers protection against cancer when tested against the modest carcinogen exposure levels most likely to be found in the environment.

13 Jan 2012

Caltech researchers devise new method to make complex molecules

A team of researchers at the California Institute of Technology (Caltech) has devised a new method for making complex molecules. The reaction they have come up with should enable chemists to synthesize new varieties of a whole subclass of organic compounds called nitrogen-containing heterocycles, thus opening up new avenues for the development of novel pharmaceuticals and natural products ranging from chemotherapeutic compounds to bioactive plant materials such as morphine.

12 Jan 2012

Nicotine patches may help individuals with early memory loss

Star Scientific, Inc. - A study released in the January 9th issue of the Journal of Neurology suggests that nicotine patches may help individuals with early memory loss.

11 Jan 2012

Chemical preservative in cosmetics can interrupt neurological development

Scientists, health officials, and manufacturers already know that a chemical preservative found in some products, including cosmetics, is harmful to people and animals in high concentrations, but a new Brown University study in tadpoles reports that it can also interrupt neurological development even in very low concentrations.

11 Jan 2012

Oramed files provisional patent application with USPTO for combination diabetes therapy

Oramed Pharmaceuticals Inc., a developer of oral drug delivery systems, announced today that it has filed a provisional patent application with the United States Patent and Trademark Office for a combination therapy of its lead compound, ORMD-0801 in combination with its oral exenatide formulation, ORMD-0901. There is no such approved combination product available on the market today.

11 Jan 2012

Now cannabis mouth spray to help ‘pot’ addicts quit

To help smokers quit there are nicotine patches and heroin users have methadone. However till date cannabis users have little choice except stop abruptly to quit. Cannabis withdrawal symptoms include severe insomnia, pot cravings and mood swings. “Although these are not life-threatening, they are significant enough to cause marked distress and lead people to go back to using the drug,” said lead researcher Jan Copeland.

10 Jan 2012

Telormedix raises 7.5 million CHF

Telormedix, a clinical stage biopharmaceutical company focused on TLR7 agonists in the treatment of cancer and inflammatory diseases, today announced that it has raised 7.5 Million CHF from existing investors Aravis Venture and Proquest Investments.

10 Jan 2012

MAL3-101 appears to have potent anti-tumor effects on multiple myeloma

A new study from SUNY Downstate Medical Center in Brooklyn, New York, shows that MAL3-101, a recently developed inhibitor of the heat shock protein 70 (Hsp70), appears to have potent anti-tumor effects on multiple myeloma, a bone marrow cancer.

10 Jan 2012

BerGenBio completes $8.8M Series A financing round

BerGenBio AS, an emerging oncology biopharma company, today announced it has completed an $8.8 million Series A financing round. The financing will be used primarily to take lead compound BGB324 into clinical trials and to develop a companion diagnostic.

9 Jan 2012

PCI Biotech focuses on localised cancer therapy with minimum side effects

Side effects are currently the biggest problem with any cancer treatment. A Norwegian biotech company is drawing closer to the goal of creating a treatment which kills only cancer cells, leaving other cells unaffected.

7 Jan 2012

GSK obtains exclusive license to ChemoCentryx's CCX354 CCR1 inhibitor for RA

ChemoCentryx, Inc., today announced that GlaxoSmithKline (GSK) has exercised its option to obtain an exclusive license for further development and worldwide commercialization of the investigational medicine CCX354, a potent and selective inhibitor of CCR1, a chemokine receptor that drives the recruitment of inflammatory cells into the joints of patients with rheumatoid arthritis (RA).

6 Jan 2012

Probiodrug secures EUR 15M for clinical development of PQ912

Probiodrug AG today announced it has secured EUR 15 million additional financing for the ongoing development of its glutaminyl cyclase (QC) inhibitor program. The lead compound, PQ912, its first QC inhibitor, is in clinical development for the treatment of Alzheimer's disease.

5 Jan 2012

Daily doses of S-equol reduce hot flashes in postmenopausal women

Daily doses of a soy germ-based nutritional supplement containing S-equol significantly improved menopausal symptoms, including significantly reducing hot flash frequency after 12 weeks according to a placebo-controlled study in postmenopausal Japanese women published in the peer-reviewed Journal of Women's Health.

5 Jan 2012